Macrogenics (MGNX) Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

Go back to Macrogenics (MGNX) Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MACROGENICS (NASDAQ: MGNX) Delayed: 4.36 -0.04 (0.91%)
Previous Close $4.40    52 Week High $36.11 
Open $4.29    52 Week Low $14.84 
Day High $4.43    P/E 11.18 
Day Low $4.11    EPS $0.39 
Volume 205,340